Status:
COMPLETED
Single-Cell Profiling of Liver-infiltrating Immune Cells of Patients with NASH- and Virus-related HCC: Implications for Immunotherapy
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Hepatocellular Carcinoma (HCC)
MASLD-HCC
Eligibility:
All Genders
18-90 years
Brief Summary
The goal of this observational study is to learn about the the immune landscape of HCC arising from different etiology, such as MASLD and viral hepatitis, at single cell level. The main question it ai...
Detailed Description
The TME is infiltrated by several populations of immune cells, among which effector cytotoxic T and NK cells mediate tumor immuno-surveillance. By contrast, inhibitory subpopulations, including CD4+ r...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- HCV-related HCC or MASLD-related HCC
- age: ≥ 18 years, ≤ 90 years
- Signature of the informed consent
- Esclusion criteria:
- Concomitant pathologies with a life expectancy of less than 12 months
- Autoimmune or chronic inflammatory diseases
- Treatment with atezolizumab, bevacizumab, sorafenib, lenvatinib, regorafenib, cabozantinib, checkpoint inhibitors, tyrosine kinase inhibitors, or anti-VEGF therapies
- Other ongoing extrahepatic malignancies or those diagnosed within the last 3 years, except for tumors resected with curative intent and with no evidence of disease recurrence for \>3 years prior to the signing of informed consent, and considered at low risk of recurrence
- HIV infection
- Lack of patient cooperation and failure to sign the informed consent
Exclusion
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06899763
Start Date
January 1 2023
End Date
December 31 2024
Last Update
March 28 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy, 27100